Geographic Variation and US County Characteristics Associated With Rapid Kidney Function Decline  by Bowe, Benjamin et al.
CLINICAL RESEARCHCorre
Resea
Syste
63106
Recei
2016;
KidneyGeographic Variation and US County
Characteristics Associated With Rapid Kidney
Function Decline
Benjamin Bowe1, Yan Xie1, Hong Xian1,2, Min Lian3 and Ziyad Al-Aly1,3,4
1Clinical Epidemiology Center, Research and Education Service, VA Saint Louis Health Care System, Saint Louis, Missouri,
USA; 2Department of Biostatistics, College for Public Health and Social Justice, Saint Louis University, Saint Louis, Missouri,
USA; 3Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA; and 4Department of
Medicine, Division of Nephrology, VA Saint Louis Health Care System, Saint Louis, Missouri, USAIntroduction: Geographic variation in the prevalence of chronic kidney disease and incidence of end-stage
renal disease has been previously reported. However, the geographic epidemiology of rapid estimated
glomerular ﬁltration rate (eGFR) decline has not been examined.
Methods: We built a longitudinal cohort of 2,107,570 US veterans to characterize the spatial epidemiology
of and examine the associations between US county characteristics and rapid eGFR decline.
Results: There were 169,029 (8.02%) with rapid eGFR decline (deﬁned as eGFR slope < –5 ml/min per 1.73
m2/year). The prevalence of rapid eGFR decline adjusted for age, race, gender, diabetes, and hypertension
varied by county from 4.10%–6.72% in the lowest prevalence quintile to 8.41%–22.04% in the highest
prevalence quintile (P for heterogeneity < 0.001). Examination of adjusted prevalence showed substantial
geographic variation in those with and without diabetes and those with and without hypertension (P for
heterogeneity < 0.001). Cohort participants had higher odds of rapid eGFR decline when living in counties
with unfavorable characteristics in domains including health outcomes (odds ratio [OR] ¼ 1.15; conﬁdence
interval [CI] ¼ 1.09–1.22), health behaviors (OR ¼ 1.08; CI ¼ 1.03–1.13), clinical care (OR ¼ 1.11;
CI ¼ 1.06–1.16), socioeconomic conditions (OR ¼ 1.15; CI ¼ 1.09–1.22), and physical environment
(OR ¼ 1.15; CI ¼ 1.01–1.20); living in counties with high percentage of minorities and immigrants was
associated with rapid eGFR decline (OR ¼ 1.25; CI ¼ 1.20–1.31). Spatial analyses suggest the presence of
cluster of counties with high prevalence of rapid eGFR decline.
Discussion: Our ﬁndings show substantial geographic variation in rapid eGFR decline among US veterans;
the variation persists in analyses stratiﬁed by diabetes and hypertension status; results show associations
between US county characteristics in domains capturing health, socioeconomic, environmental, and
diversity conditions, and rapid eGFR decline.
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and disease.1–3 Tanner et al.4 examined the geographic
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International Reports (2017) 2, 5–17CKD prevalence only modestly correlated with ESRD
incidence suggesting that the burden of CKD does not
explain geographic variation in ESRD incidence. Mills
et al.5 showed that the global burden of CKD is high,
and that signiﬁcant variation exists in the prevalence of
CKD between high-income countries and low-
and middle-income countries. Brück et al.6 examined
the geographic variation in CKD prevalence in the
European continent and identiﬁed substantial variation
that followed the same pattern in analyses stratiﬁed by
status of diabetes mellitus and hypertension—chronic
diseases generally considered major drivers of CKD
prevalence—suggesting that variation in CKD preva-
lence is likely to be due to factors other than those
traditional drivers. The development of CKD and ESRD5
CLINICAL RESEARCH B Bowe et al.: Geographic Variation in Rapid eGFR Declineis inherently dependent on the decline in estimated
glomerular ﬁltration rate (eGFR), where faster (or more
rapid) rate of eGFR decline not only leads to earlier
manifestation of kidney disease (whether development
of CKD or ESRD), but is also associated with a signiﬁ-
cant increase in risk of all-cause mortality, cardiovas-
cular mortality, hospitalizations, and readmissions.7–13
The rate of eGFR decline varies at the individual
patient level, and much is known about individual risk
factors associated with rapid kidney function
decline.14,15 The prevalence of rapid eGFR decline
might also vary by geography; however, the spatial
epidemiology of longitudinal changes in kidney func-
tion including rate of eGFR decline and of particular
interest rapid eGFR decline has not been characterized.
Furthermore, although geographic attributes of pre-
ESRD nephrology care have been described, data on
the relationship between geographic attributes, social,
economic, physical and environmental conditions of
communities, and rate of kidney function decline are
lacking.16–19
The Department of Veterans Affairs operates a na-
tional integrated network of health care systems guided
by centrally developed policies where eligible veterans
have access to the same health care resources nation-
wide—a factor that may reduce heterogeneity of care
practices. We aimed to characterize the spatial epide-
miology of rapid eGFR decline among US veterans,
identify US county characteristics associated with rapid
eGFR decline, and to undertake spatial cluster analyses
to identify areas with high prevalence (and low prev-
alence) of rapid eGFR decline.
MATERIALS AND METHODS
Patients
Using administrative data from the US Department of
Veterans Affairs (VA), we identiﬁed users of the VA
Health Care System who had an outpatient serumParƟcipants with at least one eGFR between 
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Figure 1. Cohort construction. (a) Flow diagram of cohort assembly. (b) Tim
ESRD, end-stage renal disease.
6creatinine between 1 October 2002 and 30 September
2003 with no prior history of ESRD, dialysis, or kidney
transplant, and designated the date of last eGFR mea-
surement in this time frame as time zero (T0) (n ¼
2,462,191). Patients were further selected on having at
least one other eGFR $90 days after T0 (n ¼ 2,287,495),
and followed until 30 September 2013. Participants
were then limited to those in the continental United
States and Hawaii (n ¼ 2,250,428) who had data on all
covariates, yielding an analytic cohort of 2,107,570
(Figure 1). The study was approved by the Institutional
Review Board of the VA Saint Louis Health Care Sys-
tem, Saint Louis, MO.
Data Sources
We used Department of Veterans Affairs databases
including inpatient and outpatient medical Statistical
Analysis System (SAS) datasets (that include utilization
data related to all inpatient and outpatient encounters
within the VA system) to ascertain detailed patient
demographic characteristics, location based on Federal
Information Processing Standard county codes, and
comorbidity information based on Current Procedural
Terminology codes, and International Classiﬁcation of
Diseases, Ninth Revision, Clinical Modiﬁcation (ICD-9-
CM) diagnostic and procedure codes associated with
inpatient and outpatient encounters.20–23 The VA De-
cision Support System Laboratory Results ﬁle (a
comprehensive database that includes VA-wide results
for selected laboratory tests obtained in the clinical
setting) provided information on outpatient and inpa-
tient serum creatinine measurements.20,21,24 The VA
Vital Status and Beneﬁciary Identiﬁcation Records
Locator Subsystem ﬁles provided demographic char-
acteristics and death follow-up through 30 September
2013.20,21 United States Renal Data System (USRDS)
data from the VA Centers for Medicare and Medicaid
Services were used in assessing ESRD status.25 Thectober 2002 October 2003 October 2014
e covariates and 
al locaƟon 
Ascertainment of  rate of change in 
eGFR
t least one eGFR in this period 
(Date of last eGFR measure in 
is period was designated as T0)
At least one eGFR in this 
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aries for maps. County-level variable data were ob-
tained from the 2014 County Health Rankings national
datasets.26,27 The County Health Rankings data are
publically available and include a wide scope of
county-level information with more than 50 variables
from national sources including the Center for Disease
Control, Medicare, the US Department of Agriculture,
the Behavior Risk Factor Surveillance System, the
American Community Survey, and others. Among
those, we curated a list of variables that could be
compared across state.26,27 A complete list of variables
used in this analysis including data source, deﬁnition,
and categorization is provided in Supplementary
Table S1.26
Primary Predictor Variable
The primary predictor variable for all analyses was
county. For each patient, we found the recorded Fed-
eral Information Processing Standard county code,
pertaining to the patients residential county, most
proximal and before time zero in the MED SAS inpa-
tient and outpatient data. Counties were matched
geometrically to the 2000 Census bureau shapeﬁle.
There were data for at least one patient in 3139
counties, with a median (interquartile range) number
of patients per county of 238 (103, 562). In addi-
tional analyses, we examined the association be-
tween ecologic county-level characteristics, including
rurality, poverty rate, and the percentage of African
Americans, and odds of rapid eGFR decline.
Outcomes
For all analyses, the rate of change in eGFR over time
was the primary outcome. For each patient, we calcu-
lated eGFR slope by ﬁtting an ordinary least-squares
regression line to all outpatient eGFR measures from
T0 until 30 September 2013. The slope of the regression
line (b) describes the rate of change in kidney function
(eGFR) over time. eGFR was calculated using the
abbreviated 4-variable Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation based
on age, gender, race, and serum creatinine level.28
Participants’ eGFR was censored after the occurrence
of ESRD, dialysis, or kidney transplant. All slopes
required participants to have at least one eGFR that
was$90 days from T0. Rapid eGFR decline was deﬁned
as eGFR loss of >5 ml/min per 1.73 m2/year, and stable
eGFR decline was deﬁned as eGFR loss of 0 to 1 ml/min
per 1.73 m2/year.29
Covariates
Baseline covariates were ascertained from 1 October
1999 until cohort entry (T0 between 1 October 2002 andKidney International Reports (2017) 2, 5–1730 September 2003). Covariates included age, race,
gender, diabetes mellitus, and hypertension. Race and/
or ethnicity was categorized as white, black, or other
(Latino, Asian, Native American, or other racial and/or
ethnic minority groups). Comorbidities were assigned
on the basis of relevant ICD-9-CM diagnostic and pro-
cedures codes and Current Procedural Terminology
codes in the VA Medical SAS datasets.11,30–32 Subjects
were assigned geographic location based on their
county information contained in the outpatient or
inpatient data closest but prior to T0. County-level
variable data were obtained from the 2014 County
Health Rankings national datasets.26 We evaluated the
relationship between rapid kidney function decline
and county characteristics in 6 domains including
health outcomes, health behaviors, clinical care, social
and economic factors, physical environment, and de-
mographics. Each domain represented a number of
variables (Supplementary Table S1).26 Only variables
comparable across states were used in the analyses.26Statistical Analysis
Rate of eGFR change per year was calculated using
ordinary least squares. Crude prevalence of rapid eGFR
decline (eGFR slope < –5 vs. eGFR slope $ –5) was
computed as the number of subjects with outcome per
100 US veterans during follow-up. For adjusted mea-
sures of prevalence, mixed-effect logistic regression
models were applied with covariates including age,
race, gender, diabetes, and hypertension. A mixed
model was used to account for potential intra-
correlation within a county, and thus random in-
tercepts with a compound symmetry covariance
structure at the county level were ﬁt. Covariate co-
efﬁcients were ﬁrst obtained from the mixed-effect lo-
gistic regression model and then the adjusted
prevalence rates were calculated using the least-
squared means method, where standardization was
based on the national cohort’s distribution of cova-
riates. A Wald z test of the variance at the county level
was used in assessing homogeneity at the county level.
Mixed models adjusted for age, race, and gender
were additionally run in subsamples of those with and
without diabetes, and with and without hypertension.
Forest plots of adjusted prevalences are grouped by
county quintiles, which represent those counties in the
quintile of the age-, race-, and gender-adjusted preva-
lence in the overall cohort. Median, interquartile range,
and conﬁdence intervals (CI) of county prevalence in
each quintile are shown.
To investigate ecologic predictors (odds ratio [OR])
of rapid eGFR decline, separate mixed models
were built, where stable eGFR decline (eGFR loss of 0 to7
CLINICAL RESEARCH B Bowe et al.: Geographic Variation in Rapid eGFR Decline–1 ml/min per 1.73 m2/year) served as the reference
category.29
Principal component analysis, a data reduction
method that is often used when multicollinearity is of
concern, was performed for each county variable
domain. Principal component analysis produces unique
components in descending order of explained variance
of the variables entered into analysis based on the
correlations between the variables. To aid interpreta-
tion, only the ﬁrst component was retained.33,34 The
retained components were then used in mixed-effect
logistics regression models to examine the relation-
ship between county variable domain and eGFR
decline. Factor loadings and percent variance explained
by the ﬁrst component are presented in Supplementary
Table S2. Factor scores were computed and categorized
at the county level in quartiles, where higher quartiles
consisted of higher factor scores.
Cluster analysis was performed using the Cluster and
Outlier Analysis tool in ArcMap, which uses the
Anselin Local Moran’s I statistics to test where there
are geographic clusters of counties or outliers with
prevalence that are higher or lower than the national
average.35 For the cluster analysis, the conceptualiza-
tion of spatial relationships was inverse distance. The
distance threshold used was the default threshold as
calculated by the software algorithm, which is the
minimum distance required so that all counties had at
least one neighbor used in the calculations. Missing
data were not imputed. In analyses, a 95% CI of an OR
that does not include unity was considered statistically
signiﬁcant. In all analyses, a P value of 0.05 or less was
considered statistically signiﬁcant. All statistical ana-
lyses other than cluster analysis were done using SAS
Enterprise Guide version 7.1 and SAS 9.4 (SAS Insti-
tute, Cary, NC). Geographic information system maps
and cluster analysis were done using Arc Map 10
(ESRI, Redlands, CA).
Sensitivity Analysis
To test robustness of study ﬁndings, we undertook a
number of sensitivity analyses where we additionally
adjusted overall prevalence estimates, and estimates
stratiﬁed by the presence of diabetes and hypertension,
for initial eGFR. We also repeated prevalence analyses
in a cohort restricted to participants from counties that
contributed at least 210 participants to cohort. The
number was derived from a power analysis to be able
to detect prevalence from one half to twice the preva-
lence in the national cohort.
In spatial cluster analyses, we used distance
thresholds that were 50% and 25% of the algorithm-
generated distance threshold to assess robustness of
clustering to spatial analysis parameter speciﬁcations;8we repeated the analyses using initial eGFR as an
additional covariate; and to assess the possible inﬂu-
ence of counties with low number of participants on
the cluster analyses, we performed the analyses only in
counties that contributed at least 210 cohort partici-
pants (number generated by power analysis as
described above).
RESULTS
There were 2,107,570 US veterans in the overall cohort:
169,029 (8.02%) with rapid eGFR decline deﬁned as
eGFR slope < –5 ml/min per 1.73 m2/year, and 491,441
(23.32%) with stable eGFR (deﬁned as eGFR slope 0 to
–1 ml/min per 1.73 m2/year and served as the reference
group). The demographic and clinical characteristics of
overall cohort and the rate of eGFR decline including
those with stable and rapid eGFR slope are described in
Table 1.
Rapid Kidney Function Decline and Geography
We categorized county-level prevalence of rapid eGFR
decline in quintiles. Figure 2 depicts crude prevalence of
rapid eGFR decline by county in the United States.
Crude prevalence varied substantially from 0.0%–5.24%
in the lowest quintile to 9.89%–36.84% in the highest
quintile (P for heterogeneity < 0.001). For example, the
crude prevalence was 4.45% in Garﬁeld County, Colo-
rado; 6.54% in Salt Lake County, Utah; 7.93% in
Washington County, Maine; 9.32% in Los Angeles
County, California; and 13.36% in Fulton County,
Georgia. Adjusted prevalence for age, race, gender,
diabetes, and hypertension (Figure 3) varied from
4.10%–6.72% in the lowest quintile to 8.41%–22.04%
in the highest quintile (P for heterogeneity< 0.001). For
example, the adjusted prevalence was 5.63% in Semi-
nole County, Florida; 7.25% in Lancaster, Nebraska;
7.64% in Cass County, Texas; 8.39% in Chesapeake
City, Virginia; and 11.85% inWayne, Indiana. Adjusted
prevalence stratiﬁed by status of diabetes (in those with
and without diabetes) shows that prevalence was
reduced but remained high and exhibited substantial
geographic variation in those without diabetes (P for
heterogeneity < 0.001) (Supplementary Figure S1).
Similarly, there was substantial geographic variation in
the adjusted prevalence of rapid eGFR decline in those
with diabetes (P for heterogeneity < 0.001)
(Supplementary Figure S2). Examination of adjusted
prevalence by hypertension status (in those with and
without hypertension) showed that the prevalence of
rapid eGFR decline was decreased but also remained
high with signiﬁcant geographic variation in those
without hypertension (P for heterogeneity < 0.001)
(Supplementary Figure S3). Adjusted prevalence also
varied signiﬁcantly in those with hypertension (P forKidney International Reports (2017) 2, 5–17
Table 1. Demographic and clinical characteristics of overall study cohort and by rate of eGFR decline
Overall
N [ 2,107,570
No eGFR decline
Slope ‡0
(ml/min per 1.73 m2/yr)
N [ 786,198 (37.30%)
Stable eGFR decline
Slope <0 to --1
(ml/min per 1.73 m2/yr)
N [ 491,441 (23.32%)
Mild eGFR decline
Slope < --1 to --5
(ml/min per 1.73 m2/yr)
N [ 660,902 (31.36%)
Rapid eGFR decline
Slope < --5
(ml/min per 1.73 m2/yr)
N [ 169,029 (8.02%)
Male (%) 2,009,962 (95.37) 744,617 (94.71) 469,052 (95.44) 633,751 (95.89) 162,542 (96.16)
Race (%)
White 1,724,544 (81.83) 649,437 (82.60) 411,444 (83.72) 534,167 (80.82) 129,496 (76.61)
Black 307,910 (14.61) 108,301 (13.78) 61,916 (12.60) 104,454 (15.80) 33,239 (19.66)
Other 75,116 (3.56) 28,460 (3.62) 18,081 (3.68) 22,281 (3.37) 6294 (3.72)
Median age (yr) (IQR) 62.99 (54.47, 71.83) 61.15 (53.49, 71.01) 62.17 (54.20, 71.26) 64.78 (55.42, 72.59) 66.25 (56.17, 73.68)
Hypertension (%) 1,414,075 (67.10) 500,215 (63.62) 310,190 (63.12) 472,218 (71.45) 131,452 (77.77)
Diabetes (%) 595,561 (28.26) 175,798 (22.36) 114,365 (23.27) 226,005 (34.20) 79,393 (46.97)
Death during follow-up (%) 644,029 (30.56) 228,239 (29.03) 64,557 (19.24) 203,618 (30.81) 117,615 (69.58)
ESRD, dialysis, or kidney
transplant during
follow-up (%)
107,713 (5.11) 9856 (1.25) 7183 (1.46) 46,154 (6.98) 44,520 (26.34)
Average T0 eGFR (ml/min per
1.73 m2) (SD)
75.37 (19.47) 73.10 (18.00) 77.51 (19.37) 76.30 (20.20) 76.06 (22.17)
Average ﬁnal eGFR (ml/min
per 1.73 m2) (SD)
69.26 (23.63) 80.70 (18.97) 72.93 (19.99) 59.14 (22.08) 44.93 (24.11)
Median slope (ml/min per
1.73 m2/yr) (IQR)
–0.52 (–1.97, 0.59) 0.99 (0.44, 1.99) –0.48 (–0.71, –0.25) –2.08 (–2.10, –1.50) –7.94 (–12.47, –6.07)
Median number of eGFR
measurements (IQR)
14 (8, 22) 14 (8, 21) 15 (10, 22) 16 (9, 24) 8 (4, 16)
Median duration for eGFR
slope (yr) (IQR)
9.28 (5.15, 10.00) 9.39 (5.25, 10.00) 9.72 (7.80, 10.08) 9.22 (5.64, 9.99) 2.81 (1.34, 5.23)
County-level characteristicsa
Health outcomesb (%)
1—best 439,085 (24.57) 161,655 (24.29) 106,583 (25.80) 132,242 (23.51) 32,094 (22.03)
2 638,934 (35.76) 249,708 (37.52) 148,421 (35.93) 198,941 (35.37) 51,176 (35.13)
3 463,457 (25.94) 166,270 (24.98) 102,799 (24.89) 154,630 (27.49) 40,586 (27.86)
4—worst 245,248 (13.73) 87,970 (13.22) 55,259 (13.38) 76,587 (13.62) 21,803 (14.97)
Health behaviorsc (%)
1—best 650,907 (34.82) 233,700 (33.52) 155,318 (35.69) 208,943 (35.62) 52,946 (35.17)
2 615,564 (32.92) 238,227 (34.17) 141,898 (32.61) 187,191 (31.91) 48,248 (32.04)
3 407,178 (21.78) 150,781 (21.62) 92,444 (21.24) 130,568 (22.26) 33,385 (22.17)
4—worst 195,961 (10.48) 74,568 (10.69) 45,506 (10.46) 59,902 (10.21) 15,985 (10.62)
Clinical cared (%)
1—best 626,639 (31.81) 231,723 (31.52) 152,746 (33.33) 193,799 (31.36) 48,371 (30.52)
2 555,242 (28.19) 200,082 (27.21) 127,454 (27.81) 181,029 (29.30) 46,677 (29.45)
3 459,572 (23.33) 173,127 (23.55) 104,417 (22.79) 144,387 (23.37) 37,641 (23.75)
4—worst 328,486 (16.67) 130,342 (17.73) 73,648 (16.07) 98,699 (15.97) 25,797 (16.28)
Social and economic factorse (%)
1—best 415,670 (24.47) 151,348 (23.86) 101,304 (25.88) 131,300 (24.62) 31,718 (22.76)
2 488,958 (28.79) 189,613 (29.89) 112,329 (28.69) 148,280 (27.81) 38,736 (27.80)
3 551,557 (32.47) 207,075 (32.64) 123,644 (31.58) 174,215 (32.67) 46,623 (33.46)
4—worst 242,252 (14.26) 86,363 (13.61) 54,206 (13.85) 49,406 (14.89) 22,277 (15.99)
Physical environmentf (%)
1—best 429,499 (20.93) 184,289 (23.97) 101,868 (21.25) 140,519 (21.93) 33,851 (20.72)
2 591,192 (28.80) 222,340 (28.92) 139,967 (29.19) 170,849 (26.66) 43,747 (26.77)
3 666,692 (32.48) 228,538 (29.73) 154,182 (32.16) 190,057 (29.66) 53,771 (32.91)
4—worst 365,114 (17.79) 133,565 (17.37) 83,461 (17.41) 139,466 (21.76) 32,027 (19.60)
Demographics (%)
1—lowest quartile 180,865 (8.58) 66,921 (8.51) 45,731 (9.31) 55,855 (8.45) 12,358 (7.31)
2 313,645 (14.88) 113,610 (14.45) 75,767 (15.42) 100,976 (15.28) 23,292 (13.78)
3 454,552 (21.57) 165,005 (20.99) 108,213 (22.02) 145,748 (22.05) 35,586 (21.05)
4—highest quartile 1,158,508 (54.97) 440,662 (56.05) 261,730 (53.26) 358,323 (54.22) 97,793 (57.86)
eGFR, estimated glomerular ﬁltration rate; ESRD, end-stage renal disease; IQR, interquartile range.
aCharacteristics are the first component of principal component analysis in each category. Factor loadings can be found in Supplementary Table S2. Values 1–4 represent quartiles that
we classified at the county level.
bSubcohort where data were available (n ¼ 1,786,724).
cSubcohort where data were available (n ¼ 1,869,610).
dSubcohort where data were available (n ¼ 1,698,437).
eSubcohort where data were available (n ¼ 2,052,497).
fSubcohort where data were available (n ¼ 1,969,939).
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Figure 2. Crude prevalence of rapid estimated glomerular ﬁltration rate decline. Prevalence represents number per 100 US veterans.
CLINICAL RESEARCH B Bowe et al.: Geographic Variation in Rapid eGFR Declineheterogeneity < 0.001) (Supplementary Figure S4). In
quintiles categorized based on the age-, race-, and
gender-adjusted prevalence of rapid eGFR decline, we
examined the prevalence of rapid eGFR decline based on
diabetes and hypertension status. The results show that
within each quintile, the prevalence of rapid eGFR
decline is much higher for those with diabetes and hy-
pertension (Figure 4a and b). A comparison between
quintiles in those with hypertension revealed that
median-adjusted prevalence varied from 7.30% in
quintile 1 to 10.24% in quintile 5, representing a
40.27% increase (Figure 4a). In those without hyper-
tension, median-adjusted prevalence varied from 4.97%
in quintile 1 to 6.40% in quintile 5, representing a
28.77% increase (Figure 4a). Median-adjusted preva-
lence varied from 11.69% to 14.14% (20.96% increase)
in those with diabetes, and 4.70% to 6.85% (45.74%
increase) in those without diabetes (Figure 4b), in
quintiles 1 and 5, respectively.
Association Between US County Characteristics
and Rapid eGFR Decline
In models adjusting for age, race, gender, diabetes,
hypertension, and initial eGFR, we examined the10association between rapid eGFR decline and county
characteristics in 6 domains—whose values were ob-
tained from the results of a principal component anal-
ysis and are provided in detail in Supplemental
Table S2—including health outcomes, health behav-
iors, clinical care, social and economic factors, physical
environment, and demographics. The relationship be-
tween eGFR decline and each domain is presented in
Table 2. Results of the association between rapid eGFR
decline and the variables in each domain are presented
in Supplementary Table S2. Residents of counties that
were in the worst quartile of health outcomes and
health behaviors (quartile 4) had higher odds of rapid
eGFR decline (OR ¼ 1.15; CI ¼ 1.09–1.22 and OR ¼
1.08; CI ¼ 1.03–1.13, respectively) (Table 2). Residents
living in counties where measures of access and quality
of clinical care were poorest (quartile 4) had higher
odds of rapid eGFR decline (OR ¼ 1.11; CI ¼ 1.06–
1.16). Residents of counties with poorest social and
economic conditions (quartile 4) had higher odds of
rapid eGFR decline (OR ¼ 1.15; CI ¼ 1.09–1.22). Resi-
dents living in counties in worst physical environment
quartile (quartile 4) were associated with higher odds
of rapid eGFR decline (OR ¼ 1.15; CI ¼ 1.01–1.20).Kidney International Reports (2017) 2, 5–17
Figure 3. Adjusted prevalence of rapid estimated glomerular ﬁltration rate decline. Adjusted for age, race, gender, diabetes, and hypertension.
Prevalence represents number per 100 US veterans.
B Bowe et al.: Geographic Variation in Rapid eGFR Decline CLINICAL RESEARCHResidents living in counties with higher percentage of
African Americans and other minorities, and commu-
nities with higher percentage of residents not proﬁcient
in English, were associated with higher odds of rapid
eGFR decline (OR ¼ 1.25; CI ¼ 1.20–1.31).
In mixed-effect logistic regression models, we
examined—as a measure of calibration—the association
between individual-level predictors and rapid eGFR
decline; the results were consistent with prior knowl-
edge in that age, black race, diabetes, and hypertension
were associated with increased odds of rapid eGFR
decline (Supplementary Table S3).
Spatial Cluster Analysis
We undertook spatial cluster analysis, adjusting for
age, race, gender, diabetes, and hypertension, to
identify geographic areas with clusters of high preva-
lence of rapid eGFR decline beyond what is expected
by random chance alone (Figure 5). Application of this
analysis yielded clusters of high prevalence in the
northwestern part of the USA including parts of
Washington state; in the central southern part
including much of Texas and Oklahoma; in the
southeast including Alabama, Georgia, and the Caro-
linas; and the middle eastern part around Ohio. LowKidney International Reports (2017) 2, 5–17prevalence clusters were in the Middle West part of the
USA, including Utah, Nebraska, and Wisconsin; the
northeastern part including Maine and Vermont; and
the southern tip of Florida.
Sensitivity Analyses
To test robustness of study ﬁndings, we examined the
results in additional sensitivity analyses where (a) we
additionally adjusted prevalence estimates for eGFR
(Supplementary Figure S5) and examined differences in
prevalence estimates by status of hypertension and
diabetes after adjusting for eGFR (Supplementary
Figure S6a and b); (b) we examined adjusted preva-
lence in a cohort restricted to participants from
counties that contributed at least 210 participants to
cohort (as described in the Methods section)
(Supplementary Figure S7), and examined differences
in prevalence estimates by status of hypertension and
diabetes in this restricted cohort (Supplementary
Figure S8a and b). The results were consistent with
those shown in the primary analyses.
Spatial cluster analyses were repeated with various
reduced distance thresholds, which introduced
more stringent criteria for the detection of cluster-
ing, resulting in similar high prevalence clusters11
Figure 4. Median prevalence of rapid eGFR decline by (a) hypertension and (b) diabetes status. Adjusted for age, race, and gender. Prevalence
represents number per 100 US veterans by disease status. Prevalence rates are grouped by county quintiles that are deﬁned as the quintiles of
age-, race-, and gender-adjusted prevalence in the overall cohort. Error bars represent IQR. CI, conﬁdence interval; IQR, interquartile range.
CLINICAL RESEARCH B Bowe et al.: Geographic Variation in Rapid eGFR Decline(Supplementary Figure S9a and b). Low prevalence
clusters also remained in the same areas. Cluster
analyses that also included initial eGFR as a covariate
yielded consistent results (Supplementary
Figure S10). Spatial cluster analyses undertaken in a12cohort were restricted to participants residing in
counties that contributed at least 210 persons to
cohort (as detailed in the Materials and Methods
section), resulting in a similar pattern of clustering
(Supplemental Figure S11).Kidney International Reports (2017) 2, 5–17
Table 2. County characteristics and odds of rapid estimated glomerular ﬁltration rate (eGFR) decline
Domain N Adjustment
Quartile 2 Quartile 3 Quartile 4
OR (CI) OR (CI) OR (CI)
Health outcomes 558,721 Unadjusted 1.15 (1.10, 1.21) 1.31 (1.24, 1.38) 1.26 (1.19, 1.33)
Adjusted 1.11 (1.06, 1.17) 1.25 (1.19, 1.31) 1.15 (1.09, 1.22)
Health behaviors 585,730 Unadjusted 1.02 (0.97, 1.07) 1.14 (1.08, 1.20) 1.13 (1.07, 1.19)
Adjusted 0.98 (0.94, 1.03) 1.10 (1.05, 1.15) 1.08 (1.03, 1.13)
Clinical care 616,751 Unadjusted 1.13 (1.08, 1.18) 1.21 (1.15, 1.27) 1.20 (1.15, 1.26)
Adjusted 1.11 (1.06, 1.15) 1.15 (1.10, 1.20) 1.11 (1.06, 1.16)
Social and economic factors 530,837 Unadjusted 1.09 (1.03, 1.15) 1.18 (1.12, 1.25) 1.21 (1.14, 1.28)
Adjusted 1.09 (1.03, 1.15) 1.14 (1.08, 1.21) 1.15 (1.09, 1.22)
Physical environment 642,874 Unadjusted 0.97 (0.93, 1.02) 1.07 (1.03, 1.12) 1.20 (1.15, 1.26)
Adjusted 0.96 (0.92, 1.00) 1.02 (0.98, 1.07) 1.15 (1.01, 1.20)
Demographics 660,470 Unadjusted 1.14 (1.09, 1.19) 1.20 (1.15, 1.25) 1.32 (1.26, 1.37)
Adjusted 1.12 (1.07, 1.17) 1.17 (1.12, 1.22) 1.25 (1.20, 1.31)
Quartile 1, which consisted of the lowest factor scores obtained from principal component analysis and represented the quartile with the most favorable domain conditions, served as
the reference category.
Models adjusted for age, race, gender, diabetes, hypertension, and initial eGFR.
CI, conﬁdence interval; OR, odds ratio.
B Bowe et al.: Geographic Variation in Rapid eGFR Decline CLINICAL RESEARCHDISCUSSION
Using VA national databases, we examined the
geographic characteristics of rapid eGFR decline in
the United States. Crude and adjusted prevalence
vary substantially by geography. Diabetes andFigure 5. Geographic clustering of rapid estimated glomerular ﬁltration ra
hypertension. Median (conﬁdence interval) prevalence represents numbe
Kidney International Reports (2017) 2, 5–17hypertension are major drivers of rapid eGFR decline,
but analyses adjusting for those drivers still yielded
substantial geographic variation in the prevalence of
rapid eGFR decline. There was a signiﬁcant relation-
ship between rapid eGFR decline and characteristics
of US counties in domains including health outcomes,te decline prevalence. Adjusted for age, race, gender, diabetes, and
r per 100 US veterans.
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factors, physical environment, and demographics.
Spatial cluster analysis suggests the presence of
geographic areas with high prevalence of rapid eGFR
decline, and areas with low prevalence of rapid eGFR
decline.
The analysis capitalized on the fact that the national
VAhealth care system is centrally operated and to a large
extent guided by uniform set of policies and procedures
and evenly applied resource allocation methods where
eligible veterans theoretically have access to the same
care everywhere. Despite this, our analysis shows sub-
stantial geographic heterogeneity even after adjusting
for demographics and major drivers of disease progres-
sion. The constellation of ﬁndings suggests a signiﬁcant
relationship between geographic or neighborhood fac-
tors and rapid eGFR decline. Occelli et al.36 examined the
spatial disparities in the incidence of ESRD in the Nord-
Pas-de-Calais region in northern France—a region
characterized by high population density and homoge-
neous health care provision—and found signiﬁcant
spatial disparities in gender- and age-adjusted ESRD
incident ratios that were not explained by early dialysis
initiation and strongly correlated with measures of eco-
nomic deprivation. Hao et al.17 examined geographic
variation in rates of pre-ESRD care and observed that
dialysis facilities with the lowest pre-ESRD care were
more likely to be located in urban counties with high
African American populations and low educational
attainment. Yan et al.19 examined variation in receiving
pre-ESRD care and black-white disparities and reported
that large metropolitan and rural counties had lower
percentages of patients who received pre-ESRD
nephrology care, and that regardless of geography
black patients received less care than their white coun-
terparts. Further analyses showed that state socioeco-
nomic characteristics impact the likelihood of the receipt
of predialysis nephrologist care.18 In our analyses,
geographic attributes and US county characteristics in
domains capturing social, economic conditions, physical
environment, demographic characteristics of diversity
and inclusion, and measures of quality and outcomes of
care in communities were associated with odds of rapid
eGFR decline; our ﬁndings further expand on the
existing body of evidence and speciﬁcally establishes an
association between characteristics of US counties and
rapid eGFR decline. The results further emphasize the
notion that among US veterans receiving care at the same
health care system, and where we also adjusted for
individual-level risk factors for kidney disease pro-
gression, local geographic and neighborhood factors
remain important drivers of health outcomes including
rapid eGFR decline and that the health of communities
where people live matters to individual health.14It is not clear why geographic variation in the
prevalence of rapid eGFR decline exists. Heterogeneity
or differences in dietary habits, protein intake, physical
activity, smoking rates, and local neighborhood factors
that include availability of parks, recreational space,
and public infrastructure to promote physical activity
might explain some of the variation. It is also likely that
environmental or occupational factors, variation in the
use of analgesics, and variation in exposure to heavy
metals might affect the prevalence of rapid eGFR
decline. It is also plausible that there might be local or
regional variation in care practices and access to care
(primary or specialty care) that might explain some of
the variation observed in this report. Gene-
neighborhood interactions may explain some of the
variations seen; genetic polymorphism associated with
higher risk of rapid eGFR decline may not be
geographically randomly distributed and may be
regionally concentrated in areas where we identiﬁed
clustering of rapid eGFR decline.
The spatial cluster analyses in this report suggest the
presence of areas of high prevalence of rapid eGFR
decline. The areas identiﬁed were in the state of Texas,
and the southeastern United States. It is not clear what
factors (geographic or other) are responsible for these
clusters, and it is not clear whether these same clusters
exist among non-VA patients. Zarkowsky et al. exam-
ined the presence of incident functional arteriovenous
ﬁstula in a cohort of 464,547 patients beginning hemo-
dialysis, and foundmarked regional variation in incident
functional arteriovenous ﬁstula, and risk-adjusted ESRD
mortality among ESRD networks where the networks
representing Texas and other areas in the American
South had the lowest percentage in incident arteriove-
nous ﬁstula and highest mortality risk.37 Furthermore,
analyses by Yan et al. showed that Middle Atlantic and
Southern states exhibited lower than average probabil-
ity of receipt of pre-ESRD nephrology care;18,19 inter-
estingly, these areas correspond to some of the clusters
identiﬁed in our report. Further examination of these
high prevalence clusters is needed to develop a better
understanding of the geographic determinants of higher
prevalence of rapid eGFR decline.
Our study has a number of limitations. The cohort
included mostly older white male US veterans; thus, the
results may not be generalizable to less narrowly deﬁned
populations. The imperfect nature of administrative data
and the retrospective design of the study may also lead
to sampling bias and inaccurate measurements or
misclassiﬁcation of the predictor variables. To reduce
such measurement bias, we used deﬁnitions of comorbid
illnesses that are validated for use in VA administrative
data.30–32 Cohort inclusion criteria may have resulted in
selection bias; although serum creatinine is a routinelyKidney International Reports (2017) 2, 5–17
B Bowe et al.: Geographic Variation in Rapid eGFR Decline CLINICAL RESEARCHmeasured laboratory parameter, this nevertheless re-
quires interfacing with the VA health care system, the
likelihood (or probability) of which may be higher in
people with less optimal health. Although the analyses
were adjusted for major drivers of kidney disease pro-
gression including age, race, gender, diabetes, hyper-
tension, and eGFR, it is possible that residual
confounding from unmeasured or unknown con-
founders may explain the observed variations. Our
datasets did not include information on smoking and
obesity; both are risk factors for eGFR decline and
exhibit substantial geographic variation. Residential
county was treated as static, and our analyses did not
factor in change in patient residence that may have
occurred over time. County-level characteristics data
were obtained from the 2014 County Health Rankings
dataset, and may not accurately reﬂect these character-
istics during our baseline period of ﬁscal year 2003.
County-level data were variably missing for several
counties, which could have resulted in a selection bias.
Effect sizes (OR) are modest, and because of the very
large sample size statistical signiﬁcance should be
interpreted with caution. However, in ecologic research
point estimates are often very modest, but interpreted as
meaningful and impactful in terms of public health
relevance due to the large amount of people affected in
the studied ecologies.17
The aim of this study was to characterize the spatial
epidemiology of rapid eGFR decline among users of the
VA health care system and the results do not represent
the epidemiology of fast eGFR decline in the United
States; however, the results shed some light in that
they show substantial geographic variation in rapid
eGFR decline among users of a national integrated
network of health care systems designed to reduce
disparities and variation in health practices. The results
showing that neighborhood factors and geography still
matter substantially among users of the same integrated
health care system further emphasize the importance of
taking these factors into account in considering allo-
cation of health care resources, design, planning, and
implementation of programs and initiatives to reduce
disparities, and in the study of factors that inﬂuence
human health and disease in general. Most importantly,
our study provides a framework for the examination of
the spatial epidemiology of longitudinal parameters
(eGFR slope in this report) and illustrates that beyond
the examination of cross-sectional measures of CKD and
ESRD epidemiology, the spatial epidemiology of lon-
gitudinal eGFR change over time provides important
insight to enhance our understanding of geographic
factors that might drive faster progression, and in
informing targeted intervention for areas with high
prevalence of rapid eGFR decline.Kidney International Reports (2017) 2, 5–17Black and van der Veer38 draw on the Darwinian
philosophy and note that describing and studying
variation will unlock a better understanding of disease,
and mechanisms of change. In the era of precision
medicine—largely enabled by signiﬁcant advances in
biotechnology—where much attention is being
devoted to individual-level characteristics that drive
health outcomes, it is important to remain cognizant
that ecologic conditions including social, economic,
and environmental health of communities matters to
health of individuals.39 System-level factors, and
geographic and neighborhood characteristics—the
study of which is also enabled by a parallel evolution
in data science (and the growing repertoire of routinely
collected electronic health information), geographic
information systems, and analytics—are also important
in shaping health outcomes.40–42 Attention to these
parameters in precision public health will certainly
advance our understanding of the ecologic de-
terminants of health and disease and serve to promote
public health.16,39–48
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SUPPLEMENTARY MATERIAL
Figure S1. Adjusted prevalence of rapid eGFR decline in
those without diabetes. Adjusted for age, race, and
gender. Prevalence representsnumberper 100USveterans.
Figure S2. Adjusted prevalence of rapid eGFR decline in
those with diabetes. Adjusted for age, race, and gender.
Prevalence represents number per 100 US veterans.
Figure S3. Adjusted prevalence of rapid eGFR decline in
those without hypertension. Adjusted for age, race, and
gender. Prevalence representsnumberper 100USveterans.
Figure S4. Adjusted prevalence of rapid eGFR decline in
those with hypertension. Adjusted for age, race, and
gender. Prevalence represents number per 100 US
veterans.
Figure S5. eGFR adjusted prevalence of rapid eGFR decline.
Adjusted for age, race, gender, diabetes, hypertension, and
eGFR. Prevalence represents number per 100 US veterans.15
CLINICAL RESEARCH B Bowe et al.: Geographic Variation in Rapid eGFR DeclineFigure S6. Median eGFR adjusted prevalence of rapid
eGFR decline by (a) hypertension and (b) diabetes status.
Adjusted for age, race, gender, and eGFR. Prevalence
represents number per 100 US veterans. Quintiles are
deﬁned as the quintiles of age, race, and gender
adjusted prevalence in the overall cohort. Error bars
represent IQR.
Figure S7. Adjusted prevalence of rapid eGFR decline in a
cohort with required n $ 210. Adjusted for age, race,
gender, diabetes, and hypertension. Prevalence represents
number per 100 US veterans.
Figure S8. Median adjusted prevalence of rapid eGFR
decline by (a) hypertension and (b) diabetes status in a
cohort with required n $ 210. Adjusted for age, race,
gender, and eGFR. Prevalence represents number per 100
US veterans. Quintiles are deﬁned as the quintiles of age,
race, and gender adjusted prevalence in the overall
cohort. Error bars represent IQR.
Figure S9. Geographic clustering of rapid eGFR decline
prevalence with (a) 50% and (b) 25% original distance
threshold. Adjusted for age, race, gender, diabetes, and
hypertension. Median (CI) prevalence represents number
per 100 US veterans.
Figure S10. eGFR adjusted cluster analysis of rapid eGFR
decline prevalence. Adjusted for age, race, gender,
diabetes, hypertension, and eGFR. Median (CI) prevalence
represents number per 100 US veterans.
Figure S11. Geographic clustering of eGFR decline
prevalence in a cohort with required n $ 210. Adjusted for
age, race, gender, diabetes, and hypertension. Median (CI)
prevalence represents number per 100 US veterans.
Table S1. County characteristics variable deﬁnitions, data
sources, and values.
Table S2. County characteristics and odds of rapid eGFR
decline. County characteristics were evaluated in 6
domains including health outcomes, health behaviors,
clinical care, social and economic factors, physical
environment, and demographics.
Table S3. Individual-level predictors of rapid eGFR decline.
Supplementary material is linked to the online version of
the paper at www.kireports.org.
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